|
|
|
|
| LEADER |
05198nam a2200517 4500 |
| 001 |
ocn854760796 |
| 003 |
OCoLC |
| 005 |
20180501122012.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
130731s2013 ne o 000 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e pn
|c N$T
|d OPELS
|d E7B
|d OCLCQ
|d OCLCF
|d OCLCQ
|d EBLCP
|d YDXCP
|d MHW
|d MERUC
|d UKDOC
|d IDEBK
|d DEBSZ
|d OCLCQ
|d GrThAP
|
| 019 |
|
|
|a 818119673
|a 843188325
|a 849724462
|a 865329781
|a 900633383
|
| 020 |
|
|
|a 9780124077355
|q (electronic bk.)
|
| 020 |
|
|
|a 0124077358
|q (electronic bk.)
|
| 020 |
|
|
|a 9780124077072
|
| 020 |
|
|
|a 0124077072
|
| 035 |
|
|
|a (OCoLC)854760796
|z (OCoLC)818119673
|z (OCoLC)843188325
|z (OCoLC)849724462
|z (OCoLC)865329781
|z (OCoLC)900633383
|
| 050 |
|
4 |
|a QR181
|
| 060 |
|
4 |
|a QW 504
|
| 072 |
|
7 |
|a MED
|x 044000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.079
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
0 |
|a Advances in immunology.
|n Volume 119 /
|c edited by Frederick Alt.
|
| 264 |
|
1 |
|a Amsterdam :
|b Academic Press,
|c 2013.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in Immunology ;
|v v. 119
|
| 520 |
|
|
|a Advances in Immunology, a long-established and highly respected publication, presents current developments as well as comprehensive reviews in immunology. Articles address the wide range of topics that comprise immunology, including molecular and cellular activation mechanisms, phylogeny and molecular evolution, and clinical modalities. Edited and authored by the foremost scientists in the field, each volume provides up-to-date information and directions for the future. Key features: * Contributions from leading authorities * Informs and updates on all the latest developments in the field.
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Front Cover; Advances in Immunology; Copyright; Contents; Contributors; Chapter One: The Interdisciplinary Science of T-cell Recognition; 1. Introduction; 2. The First Level of Complexity: The Kinetics and Structural Basis of TCR-pMHC Engagement; 2.1. A corner stone of T-cell biology: Kinetic and thermodynamic measurements of TCR-pMHC binding in vitro; 2.2. TCR-pMHC structure as the gold standard: Docking geometry, germline bias, and CDR3 loops; 2.3. Implications: Cross-reactivity and serial triggering.
|
| 505 |
8 |
|
|a 3. The Second Level of Complexity: The TCR-CD3 Complex and Approaches to Answers of How It Works3.1. Toward a structural understanding of the TCR-CD3 complex; 3.2. Do allosteric interactions pull the trigger?; 3.3. Coreceptor-mediated T-cell triggering?; 3.4. Formation of higher order TCR-CD3 complex structures as the defining trigger event?; 4. The Third Level of Complexity: Antigen Recognition and the Immunological Synapse; 4.1. Binding within the synapse and expected consequences; 4.2. Mechanical assays to measure 2D-kinetics; 4.3. Imaging TCR-pMHC interactions in situ.
|
| 505 |
8 |
|
|a 4.4. Synaptic factors influencing T-cell antigen recognition and activation5. Perspective; Acknowledgments; References; Chapter Two: Residual Immune Dysregulation Syndrome in Treated HIV infection; 1. The Role of Activation and Inflammation in the Natural History of Infection; 2. Inflammatory and Coagulation Indices Predict Morbidity in Treated HIV Infection; 3. Persistent CD4+ T Cell Lymphopenia Predicts Clinical Outcomes During ART; 4. Immune Activation/Inflammation Predicts Morbidity and Mortality During ART; 5. Failure to Restore Circulating CD4+ T Cells in HIV Infection.
|
| 505 |
8 |
|
|a 6. The LN in Treated HIV Infection7. The Gut in Treated HIV Infection; 8. Other Possible Drivers of Residual Immune Dysregulation in Treated HIV Infection; 8.1. Microbial translocation; 8.2. Homeostatic proliferation; 8.3. HIV replication; 8.4. Copathogens; 8.5. Inflammatory lipids; 9. Therapeutic Approaches; 9.1. Targeting residual viral replication; 9.2. Targeting chronic viral coinfections; 9.3. Targeting microbial translocation; 9.4. Interventions to improve CD4+ T cell recovery; 9.5. Targeting innate immune responses; 10. Summary; Acknowledgment; References.
|
| 505 |
8 |
|
|a Chapter Three: Developmental Plasticity of Murine and Human Foxp3+ Regulatory T Cells1. Introduction; 2. Stability and Plasticity of Regulatory T Cells; 2.1. Homeostatic stability of Foxp3+ regulatory T cells; 2.2. Programmed plasticity of Foxp3+ regulatory T cells; 3. A Transient Flexibility Model for Regulatory T Cell Plasticity; 3.1. Enhanced regulatory T cell plasticity during the initiation phase of infection; 3.2. Regulatory T cell stability during the active phase of infection; 3.3. Transient Treg cell development during the resolution phase of infection.
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
|
7 |
|a MEDICAL
|x Immunology.
|2 bisacsh
|
| 650 |
|
7 |
|a Health and Wellbeing.
|2 eflch
|
| 650 |
|
7 |
|a Immunology.
|2 fast
|0 (OCoLC)fst00968006
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Alt, Frederick W.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Advances in immunology. Volume 119
|z 9780124077072
|w (OCoLC)853505665
|
| 830 |
|
0 |
|a Advances in immunology ;
|v v. 119.
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/00652776/119
|z Full Text via HEAL-Link
|
